Clinical Trial Update: Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial comparing pegylated liposomal doxorubicin to pirarubicin plus ifosfamide and dacarbazine for locally advanced, unresectable, or metastatic soft-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Dacarbazine (dacarbazine)
• IFOSFAMIDE (IFOSFAMIDE)
• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)
• Pirarubicin (pirarubicin)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Progression-free Survival, Overall Survival | Phase 2, Phase 3 | Status: WITHDRAWN